London, September 9th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced that it had submitted a request to the MHRA for authorisation for a Phase II Clinical Study Protocol for its NM-01 product.

The study will investigate the assessment of programmed death ligand 1 (PD-L1) expression using 99mTc-NM-01 as a SPECT/CT radiotracer and its correlation to PD-L1 expression results based on routine immunohistochemical (IHC) testing in biopsy diagnostic specimens. The study will be carried out at King’s College London and Guy’s and St. Thomas’s NHS Trust with Professor Gary Cook acting as the Chief Investigator.

Paul Edwards, Nanomab’s CEO commented, “Our goal is to develop NM-01 as a common and affordable tool to enable non-invasive in vivo imaging. This would allow the measurement of PD-L1 expression before, during and after treatment within one to two hours from injection, which would provide clinicians with valuable information for patient’s treatment regime and disease progression. This could potentially be the best companion diagnostics for immune checkpoint drugs. The submission of this protocol is a significant step forward for NanoMab”

We also continue to make strong progress with NM-02, a therapeutic product for the treatment of HER2 positive cancers. We anticipate carrying out an FIH study over the next 3-4 months with the aim of commencing a Clinical Study Protocol in the next 12 months.


For more information:

Paul Edwards. Tel: +44 (0)7771 575374



Richard Hayhurst/Janet Joy RHApr

Tel: +44 (0)7711 821 527 or



Notes to editors


NanoMab Technology Limited is a privately held biopharmaceutical company focusing on cancer precision therapies via the development of radiopharmaceuticals. Our goal is to develop a pipeline of theranostics with our proprietary camelid antibody platform to address the unmet medical need for cancer patients across the world.